The Biopharma industries have had enormous societal impact during the past decades through the discovery and development of new medicines. The UK has played a leading role in this process and medicines research has been a strong driver of economic growth, a key provider of highly skilled employment and a key contributor to high quality healthcare.
 
However, the economic realities of the 21st century are forcing a reappraisal of previously successful business process and operating structures. With Big Pharma cutting research jobs and biotech companies finding it increasingly difficult to attract Venture funding, medicines research in the UK is in need of a new funding model in order to remain competitive.
 
This conference will consider the origins and potential consequences of this crisis, considering new models and approaches to reap the innovation dividend from the UK’s knowledge creation activities. In a sustainable world, wealth creation and social benefit can work hand in hand –to achieve greater value from intellectual property assets.

 

Speakers: